243 related articles for article (PubMed ID: 21916402)
1. Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold.
Cappelli A; Bini G; Valenti S; Giuliani G; Paolino M; Anzini M; Vomero S; Giorgi G; Giordani A; Stasi LP; Makovec F; Ghelardini C; Di Cesare Mannelli L; Concas A; Porcu P; Biggio G
J Med Chem; 2011 Oct; 54(20):7165-75. PubMed ID: 21916402
[TBL] [Abstract][Full Text] [Related]
2. New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.
Guerrini G; Ciciani G; Bruni F; Selleri S; Guarino C; Melani F; Montali M; Daniele S; Martini C; Ghelardini C; Norcini M; Ciattini S; Costanzo A
J Med Chem; 2010 Nov; 53(21):7532-48. PubMed ID: 20939501
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationship studies in peripheral benzodiazepine receptor ligands related to alpidem.
Cappelli A; Giuliani G; Valenti S; Anzini M; Vomero S; Giorgi G; Sogliano C; Maciocco E; Biggio G; Concas A
Bioorg Med Chem; 2008 Mar; 16(6):3428-37. PubMed ID: 18294852
[TBL] [Abstract][Full Text] [Related]
4. Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO).
Reynolds A; Hanani R; Hibbs D; Damont A; Da Pozzo E; Selleri S; Dollé F; Martini C; Kassiou M
Bioorg Med Chem Lett; 2010 Oct; 20(19):5799-802. PubMed ID: 20727749
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolo[4,3-c]quinolines, synthesis and specific inhibition of benzodiazepine receptor binding. Note II.
Savini L; Massarelli P; Corti P; Pellerano C; Bruni G; Romeo MR
Farmaco; 1993 Dec; 48(12):1675-86. PubMed ID: 8135991
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
Takahashi Y; Hashizume M; Shin K; Terauchi T; Takeda K; Hibi S; Murata-Tai K; Fujisawa M; Shikata K; Taguchi R; Ino M; Shibata H; Yonaga M
J Med Chem; 2012 Oct; 55(19):8450-63. PubMed ID: 22971011
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and preliminary pharmacological evaluation of new quinoline derivatives as nicotinic ligands.
Guandalini L; Norcini M; Varani K; Pistolozzi M; Gotti C; Bazzicalupi C; Martini E; Dei S; Manetti D; Scapecchi S; Teodori E; Bertucci C; Ghelardini C; Romanelli MN
J Med Chem; 2007 Oct; 50(20):4993-5002. PubMed ID: 17850058
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and binding studies of 1-arylpyrazolo[4,5-c]- and 2-arylpyrazolo[4,3-c]quinolin-4-ones. I.
Cecchi L; Melani F; Palazzino G; Filacchioni G; Martini C; Pennacchi E; Lucacchini A
Farmaco Sci; 1985 Jul; 40(7):509-16. PubMed ID: 2995118
[TBL] [Abstract][Full Text] [Related]
9. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
[TBL] [Abstract][Full Text] [Related]
10. Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity.
Costa B; Da Pozzo E; Chelli B; Simola N; Morelli M; Luisi M; Maccheroni M; Taliani S; Simorini F; Da Settimo F; Martini C
Psychoneuroendocrinology; 2011 May; 36(4):463-72. PubMed ID: 20728278
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationships of novel benzoxazolone derivatives as 18 kDa translocator protein (TSPO) ligands.
Fukaya T; Kodo T; Ishiyama T; Kakuyama H; Nishikawa H; Baba S; Masumoto S
Bioorg Med Chem; 2012 Sep; 20(18):5568-82. PubMed ID: 22884355
[TBL] [Abstract][Full Text] [Related]
12. Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization.
Taliani S; Da Pozzo E; Bellandi M; Bendinelli S; Pugliesi I; Simorini F; La Motta C; Salerno S; Marini AM; Da Settimo F; Cosimelli B; Greco G; Novellino E; Martini C
J Med Chem; 2010 May; 53(10):4085-93. PubMed ID: 20438080
[TBL] [Abstract][Full Text] [Related]
13. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
Lenzi O; Colotta V; Catarzi D; Varano F; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
Bioorg Med Chem; 2011 Jun; 19(12):3757-68. PubMed ID: 21616671
[TBL] [Abstract][Full Text] [Related]
15. Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images.
Damont A; Médran-Navarrete V; Cacheux F; Kuhnast B; Pottier G; Bernards N; Marguet F; Puech F; Boisgard R; Dollé F
J Med Chem; 2015 Sep; 58(18):7449-64. PubMed ID: 26280386
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.
Cappelli A; Anzini M; Castriconi F; Grisci G; Paolino M; Braile C; Valenti S; Giuliani G; Vomero S; Di Capua A; Betti L; Giannaccini G; Lucacchini A; Ghelardini C; Di Cesare Mannelli L; Frosini M; Ricci L; Giorgi G; Mascia MP; Biggio G
J Med Chem; 2016 Apr; 59(7):3353-72. PubMed ID: 26982523
[TBL] [Abstract][Full Text] [Related]
17. Structural comparisons of isomeric series of 7-aryl-benzo[h]pyrazolo[3,4-b]quinolines and 11-aryl-benzo[f]pyrazolo[3,4-b]quinolines.
Portilla J; Quiroga J; Nogueras M; de la Torre JM; Cobo J; Low JN; Glidewell C
Acta Crystallogr B; 2008 Feb; 64(Pt 1):72-83. PubMed ID: 18204214
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as potential GABA
Guerrini G; Ciciani G; Daniele S; Di Cesare Mannelli L; Ghelardini C; Martini C; Selleri S
Bioorg Med Chem; 2017 Mar; 25(6):1901-1906. PubMed ID: 28237554
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and structure-activity relationship of novel tricyclic benzimidazolone derivatives as potent 18 kDa translocator protein (TSPO) ligands.
Fukaya T; Kodo T; Ishiyama T; Nishikawa H; Baba S; Masumoto S
Bioorg Med Chem; 2013 Mar; 21(5):1257-67. PubMed ID: 23352481
[TBL] [Abstract][Full Text] [Related]
20. The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors.
Popik P; Kostakis E; Krawczyk M; Nowak G; Szewczyk B; Krieter P; Chen Z; Russek SJ; Gibbs TT; Farb DH; Skolnick P; Lippa AS; Basile AS
J Pharmacol Exp Ther; 2006 Dec; 319(3):1244-52. PubMed ID: 16971504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
